Medium-chain triglycerides improved cognition and lipid metabolomics in mild to moderate Alzheimer's disease patients with APOE4−/−: A double-blind, randomized, placebo-controlled crossover trial

Previous clinical and animal studies suggested that medium-chain triglycerides (MCT) might be an alternative energy substrate for the brain and might benefit patients with Alzheimer's disease (AD), but the clinical evidence is not substantial or totally convincing. To investigate the effects of...

Full description

Saved in:
Bibliographic Details
Published in:Clinical nutrition (Edinburgh, Scotland) Scotland), 2020-07, Vol.39 (7), p.2092-2105
Main Authors: Xu, Qing, Zhang, Yong, Zhang, Xinsheng, Liu, Lu, Zhou, Bo, Mo, Rui, Li, Yan, Li, Huizi, Li, Feng, Tao, Yang, Liu, Yinghua, Xue, Changyong
Format: Article
Language:English
Subjects:
Alzheimer's disease
Apolipoprotein E
Cognition
Medium-chain triglyceride
Metabolomics
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c356t-fea4135dbbf988333f68c891952a66289c15c8695f70438403da9d1b02f456463
cites cdi_FETCH-LOGICAL-c356t-fea4135dbbf988333f68c891952a66289c15c8695f70438403da9d1b02f456463
container_end_page 2105
container_issue 7
container_start_page 2092
container_title Clinical nutrition (Edinburgh, Scotland)
container_volume 39
creator Xu, Qing
Zhang, Yong
Zhang, Xinsheng
Liu, Lu
Zhou, Bo
Mo, Rui
Li, Yan
Li, Huizi
Li, Feng
Tao, Yang
Liu, Yinghua
Xue, Changyong
description Previous clinical and animal studies suggested that medium-chain triglycerides (MCT) might be an alternative energy substrate for the brain and might benefit patients with Alzheimer's disease (AD), but the clinical evidence is not substantial or totally convincing. To investigate the effects of MCT on cognitive ability in patients with mild to moderate AD and explore the changes in peripheral blood metabolomics. A double-blind, randomized, placebo-controlled crossover study was undertaken in 53 mild to moderate AD patients. Participants were randomized between two sequences (placebo followed by MCT or MCT followed by placebo) and took MCT jelly or placebo jelly (canola oil) by mouth three times daily (total daily fat dose: 17.3 g MCT, or 19.7 g canola oil) for 30 days per phase. The primary outcome was cognition as measured by the Alzheimer's Disease Assessment Scale–Cognitive Subscale, Chinese version (ADAS-Cog-C). The secondary outcome was self-care as measured by the activities of daily living scale (ADL) and changes in plasma metabolites. This study showed a significant (p  0.05). The concentrations of TC, HDL-C, β-hydroxybutyrate and acetoacetate were significantly higher in the MCT group than in the placebo group (p 
doi_str_mv 10.1016/j.clnu.2019.10.017
format article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2312811691</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0261561419331048</els_id><sourcerecordid>2312811691</sourcerecordid><originalsourceid>FETCH-LOGICAL-c356t-fea4135dbbf988333f68c891952a66289c15c8695f70438403da9d1b02f456463</originalsourceid><addsrcrecordid>eNp9kc1u1DAUhSMEotPCC7BA3sGCTO049jiom1FVfqSisoB15Ng3HY_8E2ynqH0C1n0p3oMnwWEKSxaWratzzz2-X1W9IHhNMOGn-7Wyfl43mHSlsMZk86haEUabmnSCPq5WuOGkZpy0R9VxSnuMMaMb8bQ6ooR37YZ1q-rnJ9BmdrXaSeNRjuba3iqIRkNCxk0x3IBGKlx7k03wSHqNrJmMRg6yHIINzqii9MgZq1EOyAUNUWZAW3u3A-MgvkpImwQyAZpkNuBzQt9N3qHt56uL9teP-9Ny3qIt0mEeLNSDNV6_QbHMKu53UN6TlQqGUKvgcwzWLpliSKmki0toaZ9VT0ZpEzx_uE-qr-8uvpx_qC-v3n88317WijKe6xFkSyjTwzB2QlBKRy6U6EjHGsl5IzpFmBK8Y-MGt1S0mGrZaTLgZmwZbzk9qV4ffMtqvs2Qcu9MUmCt9BDm1DeUNIKU9ZIibQ7SP1EjjP0UjZPxtie4XwD2-34B2C8Al1oBWJpePvjPgwP9r-UvsSI4Owig_PLGQOyTKjtVBWMElXsdzP_8fwPoCLHK</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2312811691</pqid></control><display><type>article</type><title>Medium-chain triglycerides improved cognition and lipid metabolomics in mild to moderate Alzheimer's disease patients with APOE4−/−: A double-blind, randomized, placebo-controlled crossover trial</title><source>ScienceDirect Freedom Collection</source><creator>Xu, Qing ; Zhang, Yong ; Zhang, Xinsheng ; Liu, Lu ; Zhou, Bo ; Mo, Rui ; Li, Yan ; Li, Huizi ; Li, Feng ; Tao, Yang ; Liu, Yinghua ; Xue, Changyong</creator><creatorcontrib>Xu, Qing ; Zhang, Yong ; Zhang, Xinsheng ; Liu, Lu ; Zhou, Bo ; Mo, Rui ; Li, Yan ; Li, Huizi ; Li, Feng ; Tao, Yang ; Liu, Yinghua ; Xue, Changyong</creatorcontrib><description>Previous clinical and animal studies suggested that medium-chain triglycerides (MCT) might be an alternative energy substrate for the brain and might benefit patients with Alzheimer's disease (AD), but the clinical evidence is not substantial or totally convincing. To investigate the effects of MCT on cognitive ability in patients with mild to moderate AD and explore the changes in peripheral blood metabolomics. A double-blind, randomized, placebo-controlled crossover study was undertaken in 53 mild to moderate AD patients. Participants were randomized between two sequences (placebo followed by MCT or MCT followed by placebo) and took MCT jelly or placebo jelly (canola oil) by mouth three times daily (total daily fat dose: 17.3 g MCT, or 19.7 g canola oil) for 30 days per phase. The primary outcome was cognition as measured by the Alzheimer's Disease Assessment Scale–Cognitive Subscale, Chinese version (ADAS-Cog-C). The secondary outcome was self-care as measured by the activities of daily living scale (ADL) and changes in plasma metabolites. This study showed a significant (p &lt; 0.01) reduction in ADAS-Cog-C scores between the MCT (2.62 points below baseline) and placebo interventions (2.57 points above baseline). Data from 46 (86.8%) APOE4−/− subjects who completed the entire study were analyzed. Changes in ADL scores were not significantly different between the MCT and placebo interventions (p &gt; 0.05). The concentrations of TC, HDL-C, β-hydroxybutyrate and acetoacetate were significantly higher in the MCT group than in the placebo group (p &lt; 0.05). Lysophosphatidylcholine 16:0 (LysoPC (16:0)), LysoPC (P-18:0), LysoPC (P-18:1(9Z)), LysoPC (20:2(11Z,14Z)), and LysoPC (22:5(4Z,7Z,10Z,13Z,16Z)) were significantly increased after MCT intervention, and the concentrations of LysoPC (18:0), palmitic acid, linoleic acid, oleic acid, and 7,12-dimethylbenz[a]anthracene were significantly decreased (p &lt; 0.05), whereas no significant changes appeared after the placebo intervention. Androstenedione concentration increased after placebo intervention. Furthermore, a significant negative correlation was observed between changes in LysoPC (P-18:1(9Z)) and ADAS-Cog-C scores after MCT intervention (r = −0.1472, p &lt; 0.05). MCT had positive effects on cognitive ability in mild to moderate AD patients with APOE4−/−. These effects of MCT might be related to the metabolism of LysoPC, oleic acid, linoleic acid and palmitic acid, in addition to the ketogenic effect. ChiCTR-IOR-16009737. WHO ICTRP Search Portal – http://apps.who.int/trialsearch/Default.aspx.</description><identifier>ISSN: 0261-5614</identifier><identifier>EISSN: 1532-1983</identifier><identifier>DOI: 10.1016/j.clnu.2019.10.017</identifier><identifier>PMID: 31694759</identifier><language>eng</language><publisher>England: Elsevier Ltd</publisher><subject>Alzheimer's disease ; Apolipoprotein E ; Cognition ; Medium-chain triglyceride ; Metabolomics</subject><ispartof>Clinical nutrition (Edinburgh, Scotland), 2020-07, Vol.39 (7), p.2092-2105</ispartof><rights>2019 Elsevier Ltd and European Society for Clinical Nutrition and Metabolism</rights><rights>Copyright © 2019 Elsevier Ltd and European Society for Clinical Nutrition and Metabolism. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c356t-fea4135dbbf988333f68c891952a66289c15c8695f70438403da9d1b02f456463</citedby><cites>FETCH-LOGICAL-c356t-fea4135dbbf988333f68c891952a66289c15c8695f70438403da9d1b02f456463</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27903,27904</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/31694759$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Xu, Qing</creatorcontrib><creatorcontrib>Zhang, Yong</creatorcontrib><creatorcontrib>Zhang, Xinsheng</creatorcontrib><creatorcontrib>Liu, Lu</creatorcontrib><creatorcontrib>Zhou, Bo</creatorcontrib><creatorcontrib>Mo, Rui</creatorcontrib><creatorcontrib>Li, Yan</creatorcontrib><creatorcontrib>Li, Huizi</creatorcontrib><creatorcontrib>Li, Feng</creatorcontrib><creatorcontrib>Tao, Yang</creatorcontrib><creatorcontrib>Liu, Yinghua</creatorcontrib><creatorcontrib>Xue, Changyong</creatorcontrib><title>Medium-chain triglycerides improved cognition and lipid metabolomics in mild to moderate Alzheimer's disease patients with APOE4−/−: A double-blind, randomized, placebo-controlled crossover trial</title><title>Clinical nutrition (Edinburgh, Scotland)</title><addtitle>Clin Nutr</addtitle><description>Previous clinical and animal studies suggested that medium-chain triglycerides (MCT) might be an alternative energy substrate for the brain and might benefit patients with Alzheimer's disease (AD), but the clinical evidence is not substantial or totally convincing. To investigate the effects of MCT on cognitive ability in patients with mild to moderate AD and explore the changes in peripheral blood metabolomics. A double-blind, randomized, placebo-controlled crossover study was undertaken in 53 mild to moderate AD patients. Participants were randomized between two sequences (placebo followed by MCT or MCT followed by placebo) and took MCT jelly or placebo jelly (canola oil) by mouth three times daily (total daily fat dose: 17.3 g MCT, or 19.7 g canola oil) for 30 days per phase. The primary outcome was cognition as measured by the Alzheimer's Disease Assessment Scale–Cognitive Subscale, Chinese version (ADAS-Cog-C). The secondary outcome was self-care as measured by the activities of daily living scale (ADL) and changes in plasma metabolites. This study showed a significant (p &lt; 0.01) reduction in ADAS-Cog-C scores between the MCT (2.62 points below baseline) and placebo interventions (2.57 points above baseline). Data from 46 (86.8%) APOE4−/− subjects who completed the entire study were analyzed. Changes in ADL scores were not significantly different between the MCT and placebo interventions (p &gt; 0.05). The concentrations of TC, HDL-C, β-hydroxybutyrate and acetoacetate were significantly higher in the MCT group than in the placebo group (p &lt; 0.05). Lysophosphatidylcholine 16:0 (LysoPC (16:0)), LysoPC (P-18:0), LysoPC (P-18:1(9Z)), LysoPC (20:2(11Z,14Z)), and LysoPC (22:5(4Z,7Z,10Z,13Z,16Z)) were significantly increased after MCT intervention, and the concentrations of LysoPC (18:0), palmitic acid, linoleic acid, oleic acid, and 7,12-dimethylbenz[a]anthracene were significantly decreased (p &lt; 0.05), whereas no significant changes appeared after the placebo intervention. Androstenedione concentration increased after placebo intervention. Furthermore, a significant negative correlation was observed between changes in LysoPC (P-18:1(9Z)) and ADAS-Cog-C scores after MCT intervention (r = −0.1472, p &lt; 0.05). MCT had positive effects on cognitive ability in mild to moderate AD patients with APOE4−/−. These effects of MCT might be related to the metabolism of LysoPC, oleic acid, linoleic acid and palmitic acid, in addition to the ketogenic effect. ChiCTR-IOR-16009737. WHO ICTRP Search Portal – http://apps.who.int/trialsearch/Default.aspx.</description><subject>Alzheimer's disease</subject><subject>Apolipoprotein E</subject><subject>Cognition</subject><subject>Medium-chain triglyceride</subject><subject>Metabolomics</subject><issn>0261-5614</issn><issn>1532-1983</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><recordid>eNp9kc1u1DAUhSMEotPCC7BA3sGCTO049jiom1FVfqSisoB15Ng3HY_8E2ynqH0C1n0p3oMnwWEKSxaWratzzz2-X1W9IHhNMOGn-7Wyfl43mHSlsMZk86haEUabmnSCPq5WuOGkZpy0R9VxSnuMMaMb8bQ6ooR37YZ1q-rnJ9BmdrXaSeNRjuba3iqIRkNCxk0x3IBGKlx7k03wSHqNrJmMRg6yHIINzqii9MgZq1EOyAUNUWZAW3u3A-MgvkpImwQyAZpkNuBzQt9N3qHt56uL9teP-9Ny3qIt0mEeLNSDNV6_QbHMKu53UN6TlQqGUKvgcwzWLpliSKmki0toaZ9VT0ZpEzx_uE-qr-8uvpx_qC-v3n88317WijKe6xFkSyjTwzB2QlBKRy6U6EjHGsl5IzpFmBK8Y-MGt1S0mGrZaTLgZmwZbzk9qV4ffMtqvs2Qcu9MUmCt9BDm1DeUNIKU9ZIibQ7SP1EjjP0UjZPxtie4XwD2-34B2C8Al1oBWJpePvjPgwP9r-UvsSI4Owig_PLGQOyTKjtVBWMElXsdzP_8fwPoCLHK</recordid><startdate>202007</startdate><enddate>202007</enddate><creator>Xu, Qing</creator><creator>Zhang, Yong</creator><creator>Zhang, Xinsheng</creator><creator>Liu, Lu</creator><creator>Zhou, Bo</creator><creator>Mo, Rui</creator><creator>Li, Yan</creator><creator>Li, Huizi</creator><creator>Li, Feng</creator><creator>Tao, Yang</creator><creator>Liu, Yinghua</creator><creator>Xue, Changyong</creator><general>Elsevier Ltd</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>202007</creationdate><title>Medium-chain triglycerides improved cognition and lipid metabolomics in mild to moderate Alzheimer's disease patients with APOE4−/−: A double-blind, randomized, placebo-controlled crossover trial</title><author>Xu, Qing ; Zhang, Yong ; Zhang, Xinsheng ; Liu, Lu ; Zhou, Bo ; Mo, Rui ; Li, Yan ; Li, Huizi ; Li, Feng ; Tao, Yang ; Liu, Yinghua ; Xue, Changyong</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c356t-fea4135dbbf988333f68c891952a66289c15c8695f70438403da9d1b02f456463</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>Alzheimer's disease</topic><topic>Apolipoprotein E</topic><topic>Cognition</topic><topic>Medium-chain triglyceride</topic><topic>Metabolomics</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Xu, Qing</creatorcontrib><creatorcontrib>Zhang, Yong</creatorcontrib><creatorcontrib>Zhang, Xinsheng</creatorcontrib><creatorcontrib>Liu, Lu</creatorcontrib><creatorcontrib>Zhou, Bo</creatorcontrib><creatorcontrib>Mo, Rui</creatorcontrib><creatorcontrib>Li, Yan</creatorcontrib><creatorcontrib>Li, Huizi</creatorcontrib><creatorcontrib>Li, Feng</creatorcontrib><creatorcontrib>Tao, Yang</creatorcontrib><creatorcontrib>Liu, Yinghua</creatorcontrib><creatorcontrib>Xue, Changyong</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Clinical nutrition (Edinburgh, Scotland)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Xu, Qing</au><au>Zhang, Yong</au><au>Zhang, Xinsheng</au><au>Liu, Lu</au><au>Zhou, Bo</au><au>Mo, Rui</au><au>Li, Yan</au><au>Li, Huizi</au><au>Li, Feng</au><au>Tao, Yang</au><au>Liu, Yinghua</au><au>Xue, Changyong</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Medium-chain triglycerides improved cognition and lipid metabolomics in mild to moderate Alzheimer's disease patients with APOE4−/−: A double-blind, randomized, placebo-controlled crossover trial</atitle><jtitle>Clinical nutrition (Edinburgh, Scotland)</jtitle><addtitle>Clin Nutr</addtitle><date>2020-07</date><risdate>2020</risdate><volume>39</volume><issue>7</issue><spage>2092</spage><epage>2105</epage><pages>2092-2105</pages><issn>0261-5614</issn><eissn>1532-1983</eissn><abstract>Previous clinical and animal studies suggested that medium-chain triglycerides (MCT) might be an alternative energy substrate for the brain and might benefit patients with Alzheimer's disease (AD), but the clinical evidence is not substantial or totally convincing. To investigate the effects of MCT on cognitive ability in patients with mild to moderate AD and explore the changes in peripheral blood metabolomics. A double-blind, randomized, placebo-controlled crossover study was undertaken in 53 mild to moderate AD patients. Participants were randomized between two sequences (placebo followed by MCT or MCT followed by placebo) and took MCT jelly or placebo jelly (canola oil) by mouth three times daily (total daily fat dose: 17.3 g MCT, or 19.7 g canola oil) for 30 days per phase. The primary outcome was cognition as measured by the Alzheimer's Disease Assessment Scale–Cognitive Subscale, Chinese version (ADAS-Cog-C). The secondary outcome was self-care as measured by the activities of daily living scale (ADL) and changes in plasma metabolites. This study showed a significant (p &lt; 0.01) reduction in ADAS-Cog-C scores between the MCT (2.62 points below baseline) and placebo interventions (2.57 points above baseline). Data from 46 (86.8%) APOE4−/− subjects who completed the entire study were analyzed. Changes in ADL scores were not significantly different between the MCT and placebo interventions (p &gt; 0.05). The concentrations of TC, HDL-C, β-hydroxybutyrate and acetoacetate were significantly higher in the MCT group than in the placebo group (p &lt; 0.05). Lysophosphatidylcholine 16:0 (LysoPC (16:0)), LysoPC (P-18:0), LysoPC (P-18:1(9Z)), LysoPC (20:2(11Z,14Z)), and LysoPC (22:5(4Z,7Z,10Z,13Z,16Z)) were significantly increased after MCT intervention, and the concentrations of LysoPC (18:0), palmitic acid, linoleic acid, oleic acid, and 7,12-dimethylbenz[a]anthracene were significantly decreased (p &lt; 0.05), whereas no significant changes appeared after the placebo intervention. Androstenedione concentration increased after placebo intervention. Furthermore, a significant negative correlation was observed between changes in LysoPC (P-18:1(9Z)) and ADAS-Cog-C scores after MCT intervention (r = −0.1472, p &lt; 0.05). MCT had positive effects on cognitive ability in mild to moderate AD patients with APOE4−/−. These effects of MCT might be related to the metabolism of LysoPC, oleic acid, linoleic acid and palmitic acid, in addition to the ketogenic effect. ChiCTR-IOR-16009737. WHO ICTRP Search Portal – http://apps.who.int/trialsearch/Default.aspx.</abstract><cop>England</cop><pub>Elsevier Ltd</pub><pmid>31694759</pmid><doi>10.1016/j.clnu.2019.10.017</doi><tpages>14</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0261-5614
ispartof Clinical nutrition (Edinburgh, Scotland), 2020-07, Vol.39 (7), p.2092-2105
issn 0261-5614
1532-1983
language eng
recordid cdi_proquest_miscellaneous_2312811691
source ScienceDirect Freedom Collection
subjects Alzheimer's disease
Apolipoprotein E
Cognition
Medium-chain triglyceride
Metabolomics
title Medium-chain triglycerides improved cognition and lipid metabolomics in mild to moderate Alzheimer's disease patients with APOE4−/−: A double-blind, randomized, placebo-controlled crossover trial
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-21T13%3A18%3A39IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Medium-chain%20triglycerides%20improved%20cognition%20and%20lipid%20metabolomics%20in%20mild%20to%20moderate%20Alzheimer's%20disease%20patients%20with%20APOE4%E2%88%92/%E2%88%92:%20A%20double-blind,%20randomized,%20placebo-controlled%20crossover%20trial&rft.jtitle=Clinical%20nutrition%20(Edinburgh,%20Scotland)&rft.au=Xu,%20Qing&rft.date=2020-07&rft.volume=39&rft.issue=7&rft.spage=2092&rft.epage=2105&rft.pages=2092-2105&rft.issn=0261-5614&rft.eissn=1532-1983&rft_id=info:doi/10.1016/j.clnu.2019.10.017&rft_dat=%3Cproquest_cross%3E2312811691%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c356t-fea4135dbbf988333f68c891952a66289c15c8695f70438403da9d1b02f456463%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2312811691&rft_id=info:pmid/31694759&rfr_iscdi=true